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Abstract 
A study on the SN2-type ring opening reactions of aziridines with indoles as nucleophiles is 
reported. Under gold(I) catalysis a great variety of tryptamine derivatives were prepared in good to 
excellent yields with complete stereocontrol when chiral aziridines were used. We demonstrated 
that cationic gold(I) catalysts are superior Lewis acids to the previously reported group 3, 12 and 
13 metals in term of catalyst loading and reaction yields. Moreover, complete regioselectivity was 
observed for 2-phenyl-N-tosylaziridine; whereas, regioselectivity up to 10:1 ratio was observed 
with 2-methyl-N-tosylaziridine. Finally, a preliminary study on the dearomatization reactions 
giving rise to pyrroloindolines is also reported. 
 
Introduction 
Aziridine nucleophilic ring-opening reactions have been recognized for a long time as a precious 
and reliable tool to introduce the CCN motif in a huge number of substrates.1 In the specific case 
of the indole nucleus, regioselective nucleophilic ring-opening of aziridines led to the formation of 
tryptamine derivatives, chemical synthesized or naturally occurring drugs/alkaloids with well-
defined and significant biological effects. 2  However, reported examples with indoles as 
nucleophiles are relatively rare and involve aziridines bearing an electron withdrawing group at 
nitrogen (activated aziridines) under (Lewis) acidic catalysis.3 In particular, the regiochemical 
outcome for those reactions involving C2 monosubstituted aziridines largely depends on the 
substitution pattern (Scheme 1). 
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 Scheme 1 Previously reported results on the ring opening reactions of aziridines with indoles. 
For example, indoles add regioselectively at the benzylic position of C2 aryl substituted aziridines 
under LiClO4,
3h and Sc(OTf)3/Zn(OTf)2catalysis,
3a or in the presence of an excess of BF3
3i 
(Scheme 1, eq. 1). Moving to alkyl substituted aziridines, mixtures of both conceivable 
regioisomers are isolated using Zn(OTf)2
3c as catalyst, and only one report of regioselective 
reaction in the presence of an excess of BF3 has been reported till now
3i (Scheme 1, eq. 2). 
Besides, aziridines 2-carboxylate have been involved in the synthesis of tryptophan derivatives 
using 1 equivalent of Sc(ClO4)3,
3j Sc(OTf)3
3b or Y(OTf)3
3d as promoters (Scheme 1, eq. 3). From 
data reported in scheme 1, it should be noted that working with chiral C2 substituted aziridines, 
enantiomeric pure compounds can be obtained, suggesting the involvement of a SN2-type 
mechanism for the ring-opening reaction.3i,3c Clearly, enantiomeric pure derivatives have been 
obtained in C3 selective ring opening reactions of enantiomeric pure C2 substituted 
aziridines.3b,3d,3j Furthermore, several of the reported reactions suffers from some drawbacks, i.e., 
they are performed in the presence of at least stoichiometric amount of Lewis acids, require an 
excess of aziridine/indole substrates and/or are limited in scope. 
On the other hand, indole is one of the most extensively explored heterocyclic nucleus. A plethora 
of synthetic methodologies have been developed for the assembly of the indole core4 as well as for 
the functionalization of the preformed nucleus.5 This latter goal has been mainly achieved on the 
pyrrole moiety with electrophiles, exploiting the enamine-type reactivity at the C3 carbon atom 
and the nucleophilic properties of the nitrogen atom, and, to a lesser extent, with nucleophiles, 
reversing the natural reactivity by the insertion of proper substituents at nitrogen or at C2/C3 
positions. 
Others interconnected and fascinating research areas encompass the dearomative manipulation of 
the preformed indole ring 6  for the synthesis of the indolenine core and the 
cyclization/cycloaddition reactions for the synthesis of polycyclic indole derivatives,4e,4h,4k,7 either 
common scaffolds in naturally occurring and bioactive compounds. Over the last years, the 
effectiveness of all these transformations has been notably enhanced through the development of 
new catalytic and organocatalytic processes. 
Considering these results and in step with our latest research reports on the synthesis of polycyclic 
indoles8 and indole derivatives9 under gold catalysis, we recognized gold-activated aziridines as 
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suitable electrophiles for the simple functionalization and the dearomative reactions of indoles for 
the synthesis of β-indolylamines and fused pyrrolo[2,3-b]indoles, respectively (Scheme 2). 
 
 
Scheme 2 Planned gold(I) catalyzed reactions. 
Formation of stable complexes via N-coordination of aziridines with in situ generated 
triphenylphosphine gold(I) triflate (AuPPh3OTf) has been recently described by Lorenz and co-
workers.10 These complexes are quite stable and can be isolated and characterized under standard 
laboratory conditions. Moreover, in 2007 Wu and co-workers published a gold(III) chloride/silver 
triflate catalyzed ring-opening reaction of aziridines with furan and electron-rich arenes.11 Thus, in 
the presence of 1-5% of AuCl3 and 3-15% of AgOTf in nitromethane at room temperature, the 
reaction affords the corresponding β-aryl(furyl)amines in good to excellent yields. Moreover, 
several papers dealing with the σ-phylic properties of gold species have been recently 
published.8a,12 
 
Results 
We started our investigations testing the reactivity of indoles 1a and 1h with racemic 2-phenyl-N-
tosylaziridine (2a), under conventional Lewis acid, organic acid and under gold catalysis. A 
comprehensive review of reaction conditions we tested is summarized in Table 1. 
 
Table 1. Optimization studies for the formation of tryptamine derivatives 3a and 3h. 
 
entry
a 
indole eq. of 2a catalyst (mol%) solvent T, °C time, h yield, % 
1 1a 1.1 In(OTf)3 (15 mol%) DCM rt, 40 20 42 
2 1a 1.1 Sc(OTf)3 (15 mol%) DCM rt, 40 20 21 
3 1h 1.5 Zn(NTf2)2 (15 mol%) DCE rt, 60 20 48 
4 1a 0.6 BF3·OEt2 (1.5 eq.) DCM -20 0.2 54 
5 1h 1.5 TfOH (5 mol%) DCE rt 1.5 51 
6 1h 1.5 BDHP (5 mol%)b DCE 80 20 traces 
7 1a 1.1 AuCl3 (5 mol%) AgOTf (15 mol%) CH3NO2 rt 24 23 
8 1h 1.5 AgOTf (5 mol%) DCM rt, 40 20 50 
9 1a 1.5 AgNTf2 (5 mol%) DCE 80 24 45 
10 1h 1.5 [Au(PPh3)OTf]
c (5 mol%) DCE 80 0.5 61 
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11 1h 1.5 [Au(IPr)SbF6] (5 mol%) DCE 80 0.5 79 
12 1h 1.5 [Au(JohnPhos)NTf2] (5 mol%) DCE 80 0.5 87 
13 1h 1.5 [Au(PPh3)NTf2] (5 mol%) DCE 80 0.5 80 
14 1a 1.1 [Au(JohnPhos)NTf2] (5 mol%) DCE 80 4.5 98 
a Entries 1-3, 5-14: reaction conditions: to a solution of indole (0.3 mmol) and aziridine (n equiv.) in the appropriate 
solvent (2 mL, 0.15 M), catalyst was added and the mixture was stirred for the stated time and temperature. Entry 4, 
see ref. 3i. 
b BDHP = 1,1'-binaphthyl-2,2'-diyl hydrogenphosphate. 
 
We choose to survey the reactivity of 2-alkynylindole 1h, beside simple and commercially 
available 1a, to verify the feasibility of a domino process involving nucleophilic addition of indole 
to aziridine and subsequent hydroamination of the triple bond (Table 1, compound in brackets). 
However, under tested reaction conditions, this compound has been never isolated or detected in 
the crude reaction mixtures. When the reaction works toward the formation of the desired 
compounds 3 the only isolated regioisomers arose from the C2 selective ring-opening of the 
aziridine, compounds 3a and 3h. The structure of 3a was elucidated via 1D and 2D NMR 
experiments. 13  Initially, for comparison, we tested several conventional Lewis acids under 
catalytic condition (15 mol%, entries 1-3). Instead, boron trifluoride was used under the conditions 
reported in ref. 3i (entry 4). These first attempts, however, led to the formation of the desired 
product in poor or moderate yields. Similar results were obtained in the presence of trifluoroacetic 
acid as catalyst, whereas the phosphoric acid (1,1'-binaphthyl-2,2'-diyl hydrogenphosphate) 
resulted essentially ineffective, entries 5-6. Thus, gold(III) chloride, in the presence of silver 
triflate as activating agent, was tested under the reaction conditions reported by Wu,11 entry 7. In 
this case, 3a was obtained in 23% yield. 5 mol% silver triflate, silver triflimidate or cationic 
gold(I) species resulted more effective, entries 8-14, and compounds 3a or 3h were isolated in 45-
98% yields, with [Au(JohnPhos)NTf2] as catalyst of choice. 
With these results in hand, we initially choose to test the scope of the reaction under the conditions 
reported in table 1, entry 14, changing the substituents array on the indole nucleus (Scheme 3). 
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Scheme 3 Reaction scope with 2-phenyl-N-tosylaziridines 2a and (R)2a. 
 
Product yields ranged from very good to excellent when the reaction was performed with 2-aryl, 
2-alkyl, 2-vinyl, 2-alkynyl and 2-allyl indoles (1a, 1c-f, 1h-j), with N-Me protected indoles 1b and 
1g and with indole itself (1k). The introduction of an EWG on the indole phenyl moiety is well 
tolerated (1l), whereas in the presence of an EDG, indole 1m, or of when an ethoxycarbonyl group 
is linked at C2 of the indole nucleus, indoles 1n and 1o, the corresponding tryptamine derivatives 
3m-o were obtained in moderate yields. Moreover, the reactions of indoles 1a,c-e,k were repeated 
in the presence of (R)-2-phenyl-N-tosylaziridine ((R)2a) yielding the corresponding optical active 
compounds (S)3a,c-e,k in enantiomeric excesses comparable to that of the starting aziridine. 
Next, we turned our attention to the aziridine nucleus testing the reactivity of N-tosylaziridine (2b) 
(Scheme 4). 
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 Scheme 4 Reaction scope with N-tosylaziridine 2b. 
 
The reaction works well also with the unsubstituted N-tosylaziridine (2b). Tryptamines 3p-t were 
obtained in 62-71% yield using a slight excess (1.2 equivalents) of thermally fragile 2b. Working 
with a larger excess of 2b (1.5 or 2.0 equivalents) resulted in the isolation of dirty reaction 
products, contaminated by inseparable tarry decomposition compounds arising from 2b. 
Then, we focused on the ring opening reactions of racemic 2-methyl-N-tosylaziridine (2c) with 
indoles 1 (Table 2). 
 
Table 2. Ring-opening reactions of 2-methyl-N-tosylaziridine (2c) with indoles 1. 
 
entry
a 
indole catalyst (mol%) solvent T, °C overall yield, % ratio 3/3’ 
1 1a [Au(JohnPhos)(NTf2)] (5 mol%) DCE 80 98 2:1 
2 1c [Au(JohnPhos)(NTf2)] (5 mol%) DCE 80 86 2:1 
3 1e [Au(JohnPhos)(NTf2)] (5 mol%) DCE 80 92 2:1 
4 1a BF3·OEt2 (1.5 equiv.) DCM 20 55 12:1 
5 1a [Au(JohnPhos)(SbF6)(CH3CN)] (5 mol%) DCE 80 91 1.5:1 
6 1a [Au(PPh3)(NTf2)] (5 mol%) DCE 80 31 1.5:1 
7 1a [Au(IPr)(NTf2)] (5 mol%) DCE 80 99 2:1 
8 1a [Au(IPr)(SbF6)(CH3CN)] (5 mol%) DCE 80 96 2:1 
9 1a AuCl/AgOTf (5 mol%) DCE 80 27 7:1 
10 1a AuCl/AgOTf (5 mol%) DCE 80 46 10:1 
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11 1a AuCl/AgNTf2 (5 mol%) DCE 80 70 7:1 
12 1a AuCl/AgSbF6 (5 mol%) DCE 80 70 7:1 
13 1a AgOTf (5 mol%) DCE 80 - - 
a Entries 1-3, 5-9: reaction conditions: to a solution of indole (0.3 mmol) and aziridine (1.1 equiv.) in DCE (2 mL, 
0.15 M), catalyst was added and the mixture was stirred for the stated time and temperature. Entry 4: see ref. 3i. 
Entries 10-13: reaction conditions: to a solution of indole (0.3 mmol) and aziridine (0.15 equiv.) in DCE (2 mL, 0.15 
M), catalyst was added and the mixture was stirred at 80°C for 24 h. 
 
Generally, quite unsatisfactory results were obtained working with 2-methyl-N-tosylaziridine 2c. 
The first three experiments (entries 1-3), performed with indoles 1a,c,e under standard reaction 
conditions, resulted in the isolation in excellent overall yields of an inseparable mixture of both 
conceivable regioisomeric tryptamines 3u-w and 3’u-w in 2:1 ratios. As reported in the 
introduction, regioselectivity in the ring-opening reaction of activated 2-alkylaziridines, using 
indoles as nucleophiles, is still a challenging objective and only one example of a regioselective 
reaction has been reported till now in the presence of an excess (1.5 equiv.) of boron trifluoride 
etherate.3i Thus, we performed the reaction between 1a and 2c under the conditions reported by 
Farr and co-workers (entry 4) attaining 3u and 3’u in 12:1 ratio. Next, with the aim to improve the 
regioisomeric ratios between 3 and 3’ under catalytic conditions, we tested several cationic gold(I) 
complexes varying both the ligands and the counterions (entries 5-8) achieving quite disappointing 
results. Better results could be obtained in the presence of simple gold(I) salts such as gold(I) 
triflate, generated in situ by mixing equimolecular amounts of gold(I) chloride and silver triflate. 
Thus, the reaction gave rise to compounds 3u and 3’u in 7:1 ratio (entry 9). Yield and 
regioisomeric ratio comparable to those obtained with boron trifluoride could be obtained working 
in the presence of 2 equivalents of indole 1a (entry 10). A brief screening on the silver salts nature 
was then performed revealing that AuCl/AgSbF6 and AuCl/AgNTf2 were the catalysts of choice to 
achieve 3u and 3’u in 70% yield and 7:1 ratio (entries 11-12). A control experiment performed 
with silver triflate as catalyst failed to give the desired compound (entry 13). Structures and ratios 
between the two regioisomers were assigned via NMR analysis.13 A control reaction between 
indole 1a and aziridine (S)2c under the reaction conditions reported in table 2, entry 12 resulted in 
the isolation of a mixture of (R)3u (94% ee) and 3’u in 68% overall yield (10:1 ratio) (Scheme 5). 
 
+
DCE, 80 °C, 24 h
0.15 M N
H
Ph
Me
NHTs
AuCl/AgSbF6 (5 mol%)
68%
10:1
(S)2c, ee 99.9%1a (R)3u, ee 94%
N
(S)Me
Ts
N
H
Ph
NHTs
Me
(S)3'u, ee nd
+
N
H
Ph
 
Scheme 5 Gold(I) catalyzed reaction of indole 1a and aziridine (S)2c. 
 
Moreover, several additional experiments were performed with indole 1a and aziridines 2d-f 
(Scheme 6). 
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 Scheme 6 Gold(I) catalyzed reaction of indole 1a and aziridines 2d-f. 
 
Under standard reaction conditions indole 1a reacts with aziridines 2d and 2e giving rise to 
tryptamines 3x-y in low to moderate yields, beside unreacted 1a. Moreover, the same reaction 
performed in the presence of aziridine 2f resulted in the isolation of unreacted 1a (45%) alongside 
a mixture of unidentified compounds. 
Finally, we want to report our preliminary results on the dearomative domino addition/annulation 
reactions between N,3-dimethylindole 1p, N-benzyl-3-methylindole 1q, 2,3-dimethylindole 1r and 
3-allyl-N-methylindole 1s with aziridines 2a and 2b, under cationic [Au(JohnPhos)(NTf2)] gold(I) 
catalysis (Scheme 7). 
Excellent results on related dearomative reactions, involving unsubstituted aziridine, 14 
symmetrically C2/C3 substituted aziridines15 or C2 substituted aziridines16, have been recently 
reported. 
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Scheme 7 Dearomative domino addition/annulation reactions. 
 
Under cationic gold(I) catalysis, the dearomatization reactions of indoles 1p-r with aziridine 2a 
proceeded in moderate yields giving rise to the corresponding diastereoisomeric 
dihydropyrroloindolines (±)4a-c and (±)4’a-c as racemic mixtures. Diastereoisomers (±)4a/(±)4’a 
and (±)4c/(±)4’c could be separated by column chromatography and the structures established by 
comparison with reported data16 for (±)4a and (±)4’a and by 2D NOESY experiments for (±)4c 
and (±)4’c. Diastereoisomers (±)4b/(±)4’b were characterized as a mixture via NMR and by 
comparison with reported data.16 Reactions with indoles 1p-q were repeated also in the presence 
of chiral aziridine (R)2a giving rise to enantiomeric enriched diastereoisomers 4a (96% ee) and 
4’a (96% ee) / 4b (99% ee) and 4’b (99% ee). 4a/4’a and 4b/4’b were evaluated as mixtures via 
chiral HPLC analysis, after chromatographic purification.13,17 
Working with indole 1p and aziridine 2b, the indoline 4d was obtained in 55% yield after 
optimization of the reaction conditions. In particular, the reactions performed under standard 
conditions (ratio indole/aziridine 1:1.2, 0.15 M solution in dichloroethane) at 80 and at 120°C 
under conventional heating or at temperatures ranging from 120 to 150 °C under microwaves 
irradiation gave unsatisfactory results (yields 18-39%, scheme 7, entries 1-4). A brief optimization 
study on the reagents ratios and reaction concentration revealed that doubling the equivalents of 
2b has no effect on the product yield (scheme 7, entry 5). On the other hand, working with two 
equivalents of indole 1p, at 0.3 M and 0.6 M concentrations, the desired compound could be 
isolated in 45% and 55% yields, respectively (scheme 7, entries 6-7). Under optimized reaction 
conditions, 3-allyl-N-methylindole (1s) was tested in the dearomative reaction giving rise to 
indoline 4e in 45% yield. 
 
Discussion 
As a general remark it can be stated that cationic gold(I) complexes are active catalysts in the ring-
opening reactions of activated aziridine with indoles as nucleophiles. In particular, 
[Au(JohnPhos)NTf2] is the catalyst of choice for the ring-opening reactions performed with 2-
phenyl-N-tosylaziridine 2a. Thus, the nucleophilic attack of indoles 1a-o, through C3 carbon 
atom, occurs regioselectively at the C2 of the aziridine ring, yielding the corresponding tryptamine 
derivatives 3a-o in excellent yields with a catalyst loading of only 5 mol%. Moreover, the ring-
opening reactions provide racemic mixtures when performed with achiral aziridine 2a and is 
stereospecific employing the chiral aziridine (R)2a as starting material. Based on these 
experimental results and literature reports, a reaction mechanism can be postulated for the ring-
opening reactions of 2a and (R)2a with indoles 1 (Scheme 8). Therefore, azaphilic10,18 activation 
of aziridine by cationic gold(I) catalyst produces an activated complex (I). Then the indole 1 
attacks regioselectively at the benzylic carbon of I producing a new intermediate II via a Friedel-
Craft-type reaction. Rearomatization and protodeauration steps conclude the catalytic cycle 
affording 3 and restoring the catalyst. 
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 Scheme 8 Proposed reaction mechanism. 
 
The stereospecificity attained with (R)2a accounts for the intermediacy of a strongly polarized 
specie like I, reacting with 1 via SN2-type mechanism. Besides, the intermediacy of a zwitterionic 
specie III, scheme 7, can be disregarded as it would provide racemic 3 by SN1-type mechanism. 
Unfortunately, the same regioselectivity was not observed in the ring-opening reactions involving 
2-methyl-N-tosylaziridine (2b) under [Au(JohnPhos)NTf2] catalysis. As reported in the literature 
and confirmed by our experiments (see Table 2), boron trifluoride is able to almost 
regioselectively address the nucleophilic attack at the more hindered carbon atom of the aziridine 
ring. It seems that an excess of a hard Lewis acid like boron trifluoride is essential to establish a 
strong interaction within both reacting substrates and to trigger the reaction toward the C2 
selective ring-opening reaction path.3i,19 Instead, cationic gold(I) complexes in catalytic amount 
weakly interacts with the aziridine nitrogen and, in the absence of a strong directing group like a 
phenyl ring in aziridine 2a, the reaction outcomes is driven by steric and electronic issues making 
possible two opposite reaction paths. Both of them involve ring-opening reaction of the aziridine 
2b, respectively at C2 and C3, affording mixtures of both conceivable tryptamines 3 and 3’. In line 
with these observations, it is worth to note that using 5 mol% of more electrophilic naked cationic 
gold salts improve the regioisomeric ratio between 3u and 3’u. Importantly, [Au(JohnPhos)NTf2] 
catalyst results effective also in the dearomative reactions of C3 substituted indoles. In this latter 
case, a reaction intermediate analogous to II, scheme 8, evolves by intramolecular amination 
reaction and regeneration of the catalyst. 
 
Conclusions 
In this work we established the high efficiency of cationic gold(I) catalyst [Au(JohnPhos)(NTf2)] 
in the ring opening reactions of 2-phenyl-N-tosylaziridine 2a and (R)2a with indoles as 
nucleophiles. In particular, we gathered a large collection of tryptamine derivatives in high yields, 
with complete stereochemical control and at a catalyst loading of only 5 mol%. To the best of our 
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knowledge, only sporadic examples of related Lewis acid catalyzed reactions have been reported 
till now.3h,3a,3i Furthermore, it should be pointed out that, depending on the nature of the Lewis 
acid employed, previously reported reactions could suffer from lack of stereocontrol due to 
racemization of the starting aziridine during the reaction course.16a The results obtained with 2a, 
beside those obtained with N-tosylaziridine itself (2b), represent the key strength of our work. In 
contrast, less exciting results have been achieved with 2-methyl-N-tosylaziridine (2c) and in the 
dearomative domino addition/annulation reactions. In the first case, we observed a lack of 
regiochemical control even if nearly quantitative reaction yields could be obtained. Dearomative 
reactions giving rise to pyrroloindoline derivatives, beside excellent stereocontrol, present several 
drawbacks. Moderate yields and low diastereoselection are the main weak points that must be 
addressed and further efforts in these directions are ongoing in our laboratory. Also the results 
reported for aziridines 2d-f in scheme 6 could represent a good starting point for further 
investigations. 
 
Experimental 
General Experimental Details  
All chemicals and solvents are commercially available and were used after distillation or treatment 
with drying agents. Silica gel F254 thin-layer plates were employed for thin-layer chromatography 
(TLC). Silica gel 40–63 micron/60 Å was employed for flash column chromatography. Melting 
points were measured with a Perkin- Elmer DSC 6 calorimeter at a heating rate of 5 °C/min and 
are uncorrected. 1H and 13C-NMR spectra were determined with a Varian-Gemini 200, a Bruker 
300 or 500 Avance spectrometers at room temperature in CDCl3, CD2Cl2 or d6-acetone with 
residual solvent peaks as the internal reference. The APT sequence was used to distinguish the 
methine and methyl carbon signals from those arising from methylene and quaternary carbon 
atoms. Two-dimensional NMR experiments were performed, where appropriate, to aid the 
assignment of structures. Low-resolution MS spectra were recorded with a Thermo-Finnigan LCQ 
advantage AP electrospray/ion trap equipped instrument using a syringe pump device to directly 
inject sample solutions. Microwave promoted reactions were performed with a single-mode 
Personal Chemistry microwave synthesizer “Emrys Creator,” using sealed glass vessels. The 
temperature was detected with an infrared sensor. Indoles 1a, 1e, 1k, 1n, 1o, 1p, 1r are 
commercially available and were used without any further purification. Indoles 1b-d, and 1l are 
known compounds and were prepared as reported in literature.9,20 Indoles 1q and 1s are a known 
compound and were prepared according to literature procedure.21 Indole 1h22 and indoles 1i, 1j23 
were prepared according to the procedures reported in ref. 9 and 20 (see below). Indoles 1f and 1g 
were prepared as reported in ref. 24 and 8b, respectively. 24,8b Indole 1m is a new compound and 
was prepared as reported below. Aziridines 2a-f are known compounds and were prepared 
according to standard procedures.25 AuCl3, AuCl [Au(PPh3)Cl], [Au(JohnPhos)Cl], [Au(IPr)Cl], 
AgNTf2, AgOTf, In(OTf)3, Zn(NTf)2 and TfOH were purchased from commercial suppliers and 
used as received, the rest of the gold catalysts were prepared according to literature procedures.26 
 
Preparation and characterization data for compounds 1h-j, m 
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2-(phenylethynyl)-1H-indole (1h)
22. Ethyl 2-(phenylethynyl)-1H-indole-1-carboxylate20 (0.84 g, 
2.9 mmol) was dissolved in MeOH (20 mL). Solid K2CO3 (0.40 g, 2.9 mmol) was added and the 
mixture stirred for 2 h at 40 °C. Then the solvent was removed in vacuum and the residue 
dissolved in H2O/EtOAc 1:1 (50 mL). The two phases were separated and the aqueous layer was 
extracted with EtOAc (2 x 15mL). The combined organic layers were dried over Na2SO4, filtered 
and concentrated in vacuum to yield the 2-(phenylethynyl)-1H-indole (1h) (0.59 g, 94%) as a 
yellow solid. 1H-NMR (200 MHz, CD2Cl2): δ 8.39 (s, 1H), 7.59 (m, 3H), 7.40 (m, 4H), 7.27 (t, J 
= 6.9 Hz, 1H), 7.15 (t, J = 7.3 Hz, 1H), 6.87 (s, 1H). 13C-NMR (50 MHz, CD2Cl2): δ 136.5 (C), 
131.6 (2 x CH), 128.9 (CH), 128.7 (2 x CH), 128.0 (C), 123.8 (CH), 122.8 (C), 120.9(CH), 120.7 
(CH), 119.0 (C), 111.0 (CH), 108.8 (CH), 92.6 (C), 81.8 (C). ESI-MS m/z 218 (M+H+, 100). Data 
are in agreement with those reported in ref. 22. 
2-(pent-1-yn-1-yl)-1H-indole (1i). To well stirred solution of ethyl 2-(((trifluoromethyl) 
sulfonyl)oxy)-1H-indole-1-carboxylate20 (1.0 g, 2.96 mmol) and pent-1-yne (0.24 g, 3.55 mmol) 
in dry DMF (12 mL), Pd(PPh3)4 (4 mol%, 132 mg, 0.12 mmol), CuI (2 mol%, 11.3 mg, 0.06 
mmol) and Et3N (8.25 mL, 59.2 mmol) were added. The mixture was then stirred at room 
temperature until disappearing of starting materials (c.a. 1 h) and then diluted with HCl 0.1 M 
(100 mL). Aqueous phase was extracted with EtOAc (3 x 50 mL); the combined organic phases 
were washed with brine (1 x 50 mL), dried over Na2SO4, filtered and concentrated in vacuum. 
Purification by column chromatography (Hex/EtOAc 98:2) yielded ethyl 2-(pent-1-yn-1-yl)-1H-
indole-1-carboxylate (0.72 g, 95%) as a yellow oil. 1H-NMR (200 MHz, CDCl3): δ 8.13 (d, J = 
8.2 Hz, 1H), 7.48 (m, 1H), 7.37-7.17 (m, 2H), 6.82 (s, 1H), 4.51 (q, J = 7.1 Hz, 2H), 2.48 (t, J = 
7.1 Hz, 2H), 1.68 (sextet, J = 7.1 Hz, 2H), 1.49 (t, J = 7.1 Hz, 3H), 1.08 (t, J = 7.3 Hz, 3H). Ethyl 
2-(pent-1-yn-1-yl)-1H-indole-1-carboxylate (0.72 g, 2.82 mmol) was dissolved in MeOH (19 mL). 
Solid K2CO3 (0.39 g, 2.82 mmol) was added and the mixture was stirred for 2 h at 40 °C. After 
that time, the solvent was removed in vacuum and the residue was dissolved in H2O/EtOAc 1:1 
(50 mL). The two phases were separated and aqueous layer was extracted with EtOAc (2 x 15mL). 
The combined organic layers were dried over Na2SO4, filtered and concentrated in vacuum to 
yield the 2-(pent-1-yn-1-yl)-1H-indole (1i) (0.49 g, 94%) as a brown wax. 1H-NMR (200 MHz, 
CDCl3): δ 8.09 (s, 1H), 7.56 (m, 1H), 7.35-7.02 (m, 3H), 6.66 (d, J = 1.3 Hz, 1H), 2.44 (t, J = 7.0 
Hz, 2H), 1.63 (sextet, J = 7.1 Hz, 2H), 1.07 (t, J = 7.3 Hz, 3H). 13C-NMR (50 MHz, CDCl3): δ 
136.0 (C), 128.1 (C), 123.2 (CH), 120.8 (CH), 120.5 (CH), 119.8 (C), 110.8 (CH), 107.7 (CH), 
93.9 (C), 73.4 (C), 22.3 (CH2), 21.8 (CH2), 13.8 (CH3). ESI-MS m/z 182 (M-H
+, 100). 
2-allyl-1H-indole (1j)
23. Ethyl 2-allyl-1H-indole-1-carboxylate20 (0.25 g, 1.11 mmol) was 
dissolved in MeOH (8 mL) and K2CO3 (0.15 g, 1.11 mmol) was added. The mixture was stirred 
for 30 min at 40 °C. After that time, the solvent was removed in vacuum and the residue was 
dissolved in H2O/EtOAc 1:1 (15 mL). The two phases were separated and aqueous layer was 
extracted with EtOAc (2 x 5 mL). The combined organic layers were dried over Na2SO4, filtered 
and concentrated in vacuum to yield 2-allyl-1H-indole (1j) (0.11 g, 60%) as a white solid. 1H-
NMR (200 MHz, CDCl3): δ 7.89 (s, 1H), 7.54 (d, J = 6.8 Hz, 1H), 7.36-7.00 (m, 3H), 6.28 (s, 
1H), 6.00 (m, 1H), 5.21 (m, 2H), 3.55 (d, J = 6.3 Hz, 2H). Data are in agreement with those 
reported in ref. 23. 
N,N-diethyl-1H-indol-6-amine (1m). A solution of NaOH 2M (3.7 mL, 7.49 mmol) was added to 
a stirring solution of 6-(N,N-diethylamino)-1-(phenylsulfonyl)-1H-indole27 (200 mg, 0.61 mmol) 
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in 7 mL of MeOH and heated at 85 °C under a nitrogen atmosphere. The reaction mixture was 
stirred for 24 h until no more starting product was detectable by TLC analysis. Methanol was 
removed under reduced pressure and the crude product was poured into H2O (25 mL) and 
extracted with EtOAc (4 × 20 mL), washed with brine and dried over Na2SO4. The solvent was 
removed under reduced pressure and then the residue was purified by flash chromatography over a 
silica gel column using Hex/EtOAc (7:3) to afford the N,N-diethyl-1H-indol-6-amine (1m) (95 
mg, 83%) as pale brown oil. 1H-NMR (200 MHz, CDCl3): δ 7.87 (s, 1H), 7.47 (d, J = 9.1 Hz, 
1H), 7.01 (m, 1H), 6.78 (m, 2H), 6.42 (m, 1H), 3.36 (q, J = 7.0 Hz, 4H), 1.16 (t, J = 7.0 Hz, 6H). 
13
C-NMR (C6D6, 50 MHz): δ 145.2 (C), 138.0 (C), 121.7 (CH), 121.3 (CH), 120.9 (C), 110.7 
(CH), 102.4 (CH), 96.3 (CH), 45.7 (2 x CH2), 12.7 (2 x CH3). ESI-MS m/z 189 (M+H
+, 100). 
 
Preparation and characterization data for compounds 3a-t, (S)3a, (S)3c-e, (S)3k, 3x-y 
 
Representative procedure for gold(I)-catalyzed ring opening of N-tosyl aziridines (procedure 
A). To a N2-flushed solution of indole 1a-o (1.0 equiv.) and N-tosyl aziridine 2a, (R)2a or 2b (1.1 
or 1.2 equiv.) in DCE (0.15 M), [Au(JohnPhos)(NTf2)] (5 mol%) was added and the mixture was 
stirred at 80 °C for 0.5-5 h. Solvent was then removed in vacuum and the residue purified by 
column chromatography (SiO2) to yield the corresponding product 3a-t, (S)3a, (S)3c-e, (S)3k. 
 
4-methyl-N-(2-phenyl-2-(2-phenyl-1H-indol-3-yl)ethyl)benzenesulfonamide (3a). Procedure A 
was followed using 2-phenyl-1H-indole (1a) (58 mg, 0.3 mmol), 2-phenyl-1-tosylaziridine (2a) 
(90.2 mg, 0.33 mmol) and [Au(JohnPhos)(NTf2)] (11.6 mg, 0.015 mmol) in DCE (2 mL). 
Purification of the crude by column chromatography (Hex/EtOAc 8:2) yielded 3a (137 mg, 98%) 
as a white solid (m.p.: 165-167 °C). 1H NMR (300 MHz, CDCl3): δ 8.27 (s, 1H), 7.54-7.38 (m, 
8H), 7.32-7.09 (m, 9H), 6.97 (t, J = 7.5 Hz, 1H), 4.49 (dd, J = 10.7, 6.1 Hz, 1H), 4.24 (dd, J = 9.1, 
2.8 Hz, 1H), 3.84-3.62 (m, 2H), 2.42 (s, 3H). 1H NMR (300 MHz, CDCl3 + D2O): δ 7.54-7.38 (m, 
8H), 7.32-7.09 (m, 9H), 6.97 (t, J = 7.5 Hz, 1H), 4.49 (dd, J = 10.7, 6.1 Hz, 1H), 3.80 (dd, J = 
12.2, 6.1 Hz, 1H), 3.70 (dd, J = 10.9, 12.0 Hz, 1H), 2.41 (s, 3H). 13C NMR (50 MHz, 
CDCl3): δ 143.4 (C), 141.9 (C), 138.0 (C), 136.5 (C), 136.4 (C), 132.4 (C), 129.8 (2 x CH), 129.1 
(2 x CH), 128.9 (2 x CH), 128.8 (2 x CH), 128.6 (CH), 127.9 (2 x CH), 127.3 (C), 127.2 (2 x CH), 
126.9 (CH), 122.7 (CH), 120.4 (CH), 120.3 (CH), 111.8 (CH), 109.7 (C), 46.9 (CH2), 42.5 (CH), 
21.8 (CH3). ESI-MS m/z 465 (M-H
+, 100). Calcd. for C29H26N2O2S [466.59]: C 74.65, H 5.62, N 
6.00; found C 74.38, H 5.78, N 5.86. 
(S)-4-methyl-N-(2-phenyl-2-(2-phenyl-1H-indol-3-yl)ethyl)benzenesulfonamide ((S)3a). 
Procedure A was followed using (R)-2-phenyl-1-tosylaziridine ((R)2a). (S)3a was obtained in 98% 
yield and 97% ee. (S)3a was analyzed via chiral-HPLC in comparison with racemic 3a, see 
supporting information (HPLC section) for details. 
4-methyl-N-(2-(1-methyl-2-phenyl-1H-indol-3-yl)-2-phenylethyl)benzenesulfonamide (3b). 
Procedure A was followed using 1-methyl-2-phenyl-1H-indole (1b) (62 mg, 0.3 mmol), 2-phenyl-
1-tosylaziridine (2a) (90.2 mg, 0.33 mmol) and [Au(JohnPhos)(NTf2)] (11.6 mg, 0.015 mmol) in 
DCE (2 mL). Purification of the crude by column chromatography (Hex/EtOAc 8:2) yielded 3b 
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(137 mg, 95%) as a white thick oil. 1H-NMR (300 MHz, CDCl3): δ 7.55-7.12 (m, 17H), 6.95 (t, J 
= 7.0 Hz, 1H), 4.25 (dd, J = 10.6, 6.6 Hz, 1H), 3.72-3.51 (m, 5H), 2.44 (s, 3H). 13C-NMR (75 
MHz, CDCl3): δ 143.6 (C), 142.2 (C), 140.9 (C), 137.8 (C), 136.6 (C) 131.5 (C), 131.2 (2 x CH), 
130.0 (2 x CH), 129.0 (CH), 128.9 (2 x CH), 128.8 (2 x CH), 128.0 (2 x CH), 127.5 (2 x CH), 
126.9 (CH), 126.2 (C), 122.3 (CH), 120.2 (CH), 120.1 (CH), 110.3 (C), 110.2 (CH), 46.9 (CH2), 
42.8 (CH), 31.3 (CH3), 21.9 (CH3). ESI-MS m/z 503 [M + Na
+, 100]. Calcd. for C30H28N2O2S 
[480.63]: C 74.97, H 5.87, N 5.83; found C 75.29, H 5.71, N 5.97. 
N-(2-(2-(4-isopropoxyphenyl)-1H-indol-3-yl)-2-phenylethyl)-4-methylbenzenesulfonamide 
(3c). Procedure A was followed using 2-(4-isopropoxyphenyl)-1H-indole (1c) (75.4 mg, 0.3 
mmol), 2-phenyl-1-tosylaziridine (2a) (90.2 mg, 0.33 mmol) and [Au(JohnPhos)(NTf2)] (11.6 mg, 
0.015 mmol) in DCE (2 mL). Purification of the crude by column chromatography (Hex/EtOAc 
8:2) yielded 3c (142 mg, 90%) as a white solid (m.p.: 75-78 °C). 1H-NMR (200 MHz, 
CDCl3): δ 8.18 (s, 1H), 7.50-7.36 (m, 3H), 7.32-7.08 (m, 11H), 6.97-6.85 (m, 3H), 4.59 (hept, J = 
6.0 Hz, 1H), 4.45 (dd, J = 10.7, 6.2 Hz, 1H), 4.22 (dd, J = 9.0, 2.9 Hz, 1H), 3.84-3.55 (m, 2H), 
2.40 (s, 3H), 1.39 (d, J = 6.2 Hz, 3H), 1.37 (d, J = 6.0 Hz, 3H). 13C-NMR (50 MHz, 
CDCl3): δ 158.5 (C), 143.3 (C), 142.0 (C), 138.0 (C), 136.5 (C), 136.3 (C), 130.1 (2 x CH), 129.8 
(2 x CH), 128.8 (2 x CH), 127.9 (2 x CH), 127.4 (C), 127.2 (2 x CH), 126.9 (CH), 124.4 (C), 
122.4 (CH), 120.3 (CH), 120.1 (CH), 116.3 (2 x CH), 111.4 (CH), 109.1 (C), 70.3 (CH), 46.8 
(CH2), 42.4 (CH), 22.3 (CH3), 22.2 (CH3), 21.7 (CH3). ESI-MS m/z 523 [M – H
+, 100]. Calcd. for 
C32H32N2O3S [524.67]: C 73.25, H 6.15, N 5.34; found: C 73.02, H 6.27, N 5.49. 
(S)-N-(2-(2-(4-isopropoxyphenyl)-1H-indol-3-yl)-2-phenylethyl)-4-
methylbenzenesulfonamide ((S)3c). Procedure A was followed using (R)-2-phenyl-1-
tosylaziridine ((R)2a). (S)3c was obtained in 89% yield and 98% ee. (S)3c was analyzed via chiral-
HPLC in comparison with racemic 3c, see supporting information (HPLC section) for details. 
N-(2-(2-(3-acetylphenyl)-1H-indol-3-yl)-2-phenylethyl)-4-methylbenzenesulfonamide (3d). 
Procedure A was followed using 1-(3-(1H-indol-2-yl)phenyl)ethanone (1d) (70.6 mg, 0.3 mmol), 
2-phenyl-1-tosylaziridine (2a) (90.2 mg, 0.33 mmol) and [Au(JohnPhos)(NTf2)] (11.6 mg, 0.015 
mmol) in DCE (2 mL). Purification of the crude by column chromatography (Hex/EtOAc 7:3) 
yielded 3d (148 mg, 97%) as a yellowish solid (m.p.: 77-79 °C). 1H-NMR (200 MHz, 
CDCl3): δ 8.92 (s, 1H), 7.89 (m, 2H), 7.64 -7.05 (m, 14H), 6.96 (t, J = 7.2, 1H), 4.48 (m, 2H), 3.75 
(m, 2H), 2.42 (s, 3H), 2.37 (s, 3H). 13C NMR (50 MHz, CDCl3): δ 198.2 (C), 143.5 (C), 141.8 
(C), 137.7 (C), 136.8 (C), 136.7 (C), 136.6 (C), 133.3 (CH), 133.0 (C), 129.8 (2 x CH), 129.3 
(CH), 128.9 (2 x CH), 128.9 (CH), 128.0 (2 x CH), 127.3 (C), 127.2 (2 x CH), 127.1 (CH), 122.9 
(CH), 120.5 (CH), 120.3 (CH), 112.0 (CH), 110.4 (C), 47.1 (CH2), 43.0 (CH), 26.8 (CH3), 21.7 
(CH3). 1 CHar is overlapping probably with 2xCH at 128.0. ESI-MS m/z 507 [M – H
+, 100]. 
Calcd. for C31H28N2O3S [508.63]: C 73.20, H 5.55, N 5.51; found: C 73.58, H. 5.41, N. 5.62. 
(S)-N-(2-(2-(3-acetylphenyl)-1H-indol-3-yl)-2-phenylethyl)-4-methylbenzenesulfonamide 
((S)3d). Procedure A was followed using (R)-2-phenyl-1-tosylaziridine ((R)2a). (S)3d was 
obtained in 97% yield and 97% ee. (S)3d was analyzed via chiral-HPLC in comparison with 
racemic 3d, see supporting information (HPLC section) for details. 
4-methyl-N-(2-(2-methyl-1H-indol-3-yl)-2-phenylethyl)benzenesulfonamide (3e). Procedure A 
was followed using 2-methyl-1H-indole (1e) (39.4 mg, 0.3 mmol), 2-phenyl-1-tosylaziridine (2a) 
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(90.2 mg, 0.33 mmol) and [Au(JohnPhos)(NTf2)] (11.6 mg, 0.015 mmol) in DCE (2 mL). 
Purification of the crude by column chromatography (Hex/EtOAc 8:2) yielded 3e (112 mg, 92%) 
as a white solid (m.p.: 147-150 °C). 1H-NMR (200 MHz, CDCl3): δ 7.97 (s, 1H), 7.62 (d, J = 8.3 
Hz, 2H), 7.31-7.08 (m, 9H), 6.90 (t, J = 7.4 Hz, 1H), 4.41 (dd, J = 10.4, 6.1 Hz, 1H), 4.33 (dd, J = 
8.9, 2.9 Hz, 1H), 3.84 (ddd, J = 12.1, 9.1, 6.2, 1H), 3.61 (ddd, J = 12.1, 10.6, 3.2, 1H), 2.45 (s, 
3H), 2.33 (s, 3H). 1H-NMR (200 MHz, CDCl3 + D2O): δ 7.62 (d, J = 8.3 Hz, 2H), 7.31-7.08 (m, 
9H), 6.90 (t, J = 7.4 Hz, 1H), 4.41 (dd, J = 10.5, 6.1 Hz, 1H), 4.33 (dd, J = 8.9, 2.9 Hz, 1H), 3.83 
(dd, J = 12.1, 6.1, 1H), 3.60 (dd, J = 12.1, 10.6, 1H), 2.45 (s, 3H), 2.32 (s, 3H). 13C NMR (50 
MHz, CDCl3): δ 143.7 (C), 141.7 (C), 136.7 (C), 135.8 (C), 133.9 (C), 130.0 (2 x CH), 128.8 (2 x 
CH), 127.9 (2 x CH), 127.3 (2 x CH), 127.2 (C), 126.8 (CH), 121.4 (CH), 119.8 (CH), 118.9 
(CH), 111.1 (CH), 109.2 (C), 46.6 (CH2), 42.3 (CH), 21.8 (CH3), 12.2 (CH3). ESI-MS m/z 403 [M 
– H+, 100]. Calcd. for C24H24N2O2S [404.52]: C 71.26, H 5.98, N 6.93; found: C 71.48, H 6.02, N 
6.80. 
4-methyl-N-(2-phenyl-2-(2-vinyl-1H-indol-3-yl)ethyl)benzenesulfonamide (3f). Procedure A 
was followed using ethyl 2-vinyl-1H-indole (1f) (42.9 mg, 0.3 mmol), 2-phenyl-1-tosylaziridine 
(2a) (90.2 mg, 0.33 mmol) and [Au(JohnPhos)(NTf2)] (11.6 mg, 0.015 mmol) in DCE (2 mL). 
Purification of the crude by column chromatography (Hex/EtOAc 3:1) yielded 3f (112 mg, 90%) 
as a white solid (m.p.: 130-132 °C). 1H-NMR (200 MHz, CDCl3): δ 8.23 (s, 1H), 7.60 (d, J = 8.3 
Hz, 2H), 7.32-7.14 (m, 10H), 6.88 (ddd, J = 8.2, 6.9, 1.1 Hz, 1H), 6.69 (dd, J = 17.5, 11.3 Hz, 
1H), 5.52 (d, J = 17.6 Hz, 1H), 5.28 (d, J = 11.3 Hz, 1H), 4.49 (dd, J = 10.3, 6.1 Hz, 1H), 4.30 (dd, 
J = 8.7, 3.4 Hz, 1H), 3.87 (m, 1H), 3.62 (m, 1H), 2.43 (s, 3H). 13C-NMR (50 MHz, 
CDCl3): δ 143.6 (C), 141.1 (C), 136.9 (C), 136.7 (C), 134.3 (C), 129.9 (2 x CH), 128.8 (2 x CH), 
127.8 (2 x CH), 127.3 (2 x CH), 127.2 (C), 126.9 (CH), 125.3 (CH), 123.4 (CH), 120.3 (CH), 
120.1 (CH), 113.6 (CH2), 113.0 (C), 111.3 (CH), 46.5 (CH2), 41.8 (CH), 21.8 (CH3). ESI-MS m/z 
439 [M + Na+, 100]. Calcd. for C25H24N2O2S [416.54]: C 72.09, H 5.81, N 6.73; C 72.37, H 5.88, 
N 6.72. 
(E)-4-methyl-N-(2-(1-methyl-2-(4-methylstyryl)-1H-indol-3-yl)-2-
phenylethyl)benzenesulfonamide (3g). Procedure A was followed using ethyl (E)-1-methyl-2-(4-
methylstyryl)-1H-indole (1g) (74.2 mg, 0.3 mmol), 2-phenyl-1-tosylaziridine (2a) (90.2 mg, 0.33 
mmol) and [Au(JohnPhos)(NTf2)] (11.6 mg, 0.015 mmol) in DCE (2 mL). Purification of the 
crude by column chromatography (Hex/EtOAc 8:2) yielded 3g (108 mg, 69%) as a yellow wax. 
1
H-NMR (200 MHz, CDCl3): δ 7.55 (d, J = 8.3 Hz, 2H), 7.37-7.10 (m, 14H), 6.94 (m, 2H), 6.64 
(d, J = 16.5 Hz, 1H), 4.58 (dd, J = 10.5, 6.3 Hz, 1H), 4.30 (dd, J = 8.8, 3.1 Hz, 1H), 3.84-3.59 (m, 
5H), 2.39 (s, 3H), 2.34 (s, 3H). 13C-NMR (50 MHz, CDCl3): δ 143.4 (C), 142.2 (C), 138.6 (C), 
138.1 (C), 137.7 (C), 136.7 (C), 135.7 (CH), 134.1 (C), 129.8 (2 x CH) , 129.7 (2 x CH), 128.9 (2 
x CH), 128.0 (2 x CH), 127.3 (2 x CH), 126.9 (CH), 126.8 (2 x CH), 126.6 (C), 122.4 (CH), 120.1 
(CH), 119.8 (CH), 115.7 (CH), 110.7 (C), 109.8 (CH), 47.0 (CH2), 43.2 (CH), 31.1 (CH3), 21.6 
(CH3), 21.5 (CH3). ESI-MS m/z 519 [M – H
+, 100]. Calcd. for C33H32N2O2S [520.68]: C 76.12, H 
6.19, N 5.38; found C 76.23, H 6.02, N 5.49. 
4-methyl-N-(2-phenyl-2-(2-(phenylethynyl)-1H-indol-3-yl)ethyl)benzenesulfonamide (3h). 
Procedure A was followed using 2-(phenylethynyl)-1H-indole (1h) (65.2 mg, 0.3 mmol), 2-
phenyl-1-tosylaziridine (2a) (90.2 mg, 0.33 mmol) and [Au(JohnPhos)(NTf2)] (11.6 mg, 0.015 
mmol) in DCE (2 mL). Purification of the crude by column chromatography (Hex/EtOAc 8:2) 
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yielded 3h (128 mg, 87%) as a yellowish solid (m.p.: 190-192 °C). 1H-NMR (200 MHz, d6-
Acetone): δ 10.59 (s, 1H), 7.70 (d, J = 8.3 Hz, 2H), 7.57-7.41 (m, 8H), 7.39-7.09 (m, 7H), 6.99 (t, 
J = 7.0 Hz, 1H), 6.49 (t, J = 5.5 Hz, 1H), 4.74 (t, J = 8.0 Hz, 1H), 4.08-3.80 (m, 2H), 2.34 (s, 3H). 
13
C-NMR (50 MHz, d6-Acetone): δ 143.0 (C), 142.6 (C), 138.4 (C), 136.9 (C), 131.3 (2 x CH), 
129.7 (2 x CH), 128.9 (2 x CH), 128.5 (2 x CH), 128.2 (2 x CH), 127.1 (2 x CH), 126.8 (C), 126.6 
(CH), 123.5 (CH), 123.0 (C), 121.4 (C), 119.9 (CH), 119.5 (CH), 116.8 (C), 111.5 (CH), 95.0 (C), 
82.3 (C), 46.8 (CH2), 43.5 (CH), 20.7 (CH3). 1 CHar is missing, probably overlapping. ESI-MS 
m/z 489 [M – H+, 100]. Calcd. for C31H26N2O2S [490.62]: C 75.89, H 5.34, N 5.71; found: C 
76.22, H 5.28, N 5.93. 
4-methyl-N-(2-(2-(pent-1-yn-1-yl)-1H-indol-3-yl)-2-phenylethyl)benzenesulfonamide (3i). 
Procedure A was followed using 2-(pent-1-yn-1-yl)-1H-indole (1i) (55 mg, 0.3 mmol), 2-phenyl-
1-tosylaziridine (2a) (90.2 mg, 0.33 mmol) and [Au(JohnPhos)(NTf2)] (11.6 mg, 0.015 mmol) in 
DCE (2 mL). Purification of the crude by column chromatography (Hex/EtOAc 5:1) yielded 3i 
(127 mg, 93%) as a white solid (m.p.: 126-128 °C). 1H-NMR (200 MHz, CDCl3): δ 8.06 (s, 1H), 
7.60 (d, J = 8.3 Hz, 2H), 7.31-7.07 (m, 9H), 6.92 (t, J = 6.7 Hz, 2H), 4.48 (m, 2H), 3.80 (dd, J = 
8.1, 6.3 Hz, 2H), 2.47-2.29 (m, 5H), 1.71-1.53 (m, 2H), 1.02 (t, J = 7.3 Hz, 3H). 13C-NMR (50 
MHz, CDCl3): δ 143.4 (C), 141.4 (C), 137.2 (C), 135.9 (C), 129.8 (2 x CH), 128.8 (2 x CH), 128.0 
(2 x CH), 127.3 (2 x CH), 127.0 (CH), 126.5 (C), 123.6 (CH), 120.3 (CH), 119.3 (CH), 118.4 (C), 
118.0 (C), 111.1 (CH), 97.4 (C), 72.7 (C), 46.5 (CH2), 43.0 (CH), 22.2 (CH2), 21.8 (CH3), 21.7 
(CH2), 13.9 (CH3). ESI-MS m/z 455 [M – H
+, 100]. Calcd. for C28H28N2O2S [456.60]: C 73.65, H 
6.18, N 6.14; C 73.37, H 6.12, N 6.26. 
N-(2-(2-allyl-1H-indol-3-yl)-2-phenylethyl)-4-methylbenzenesulfonamide (3j). Procedure A 
was followed using ethyl 2-allyl-1H-indole (1j) (47.2 mg, 0.3 mmol), 2-phenyl-1-tosylaziridine 
(2a) (90.2 mg, 0.33 mmol) and [Au(JohnPhos)(NTf2)] (11.6 mg, 0.015 mmol) in DCE (2 mL). 
Purification of the crude by column chromatography (Hex/EtOAc 7:3) yielded 3j (103 mg, 80%) 
as a white wax. 1H NMR (200 MHz, CDCl3): δ 7.99 (s, 1H), 7.60 (d, J = 8.2, 2H), 7.37-7.03 (m, 
10H), 6.89 (t, J = 7.5, 1H), 5.87 (m, 1H), 5.2- 5.05 (m, 2H), 4.42 (dd, J = 10.4, 6.2 Hz, 1H), 4.31 
(dd, J = 9.0, 3.4 Hz, 1H), 3.82 (m, 1H), 3.59 (m, 1H), 3.42 (d, J = 6.4 Hz, 2H), 2.43 (s, 3H). 13C 
NMR (50 MHz, CDCl3): δ 143.6 (C), 141.5 (C), 136.9 (C), 136.0 (C), 135.2 (C), 134.7 (CH), 
129.9 (2 x CH), 128.7 (2 x CH), 127.9 (2 x CH), 127.3 (2 x CH), 127.2 (C), 126.8 (CH), 121.7 
(CH), 119.9 (CH), 119.3 (CH), 117.9 (C), 111.2 (CH), 109.7 (CH), 46.6 (CH2), 42.2 (CH), 31.0 
(CH2), 21.7 (CH3). ESI-MS m/z 429 [M – H
+, 100]. Calcd. for C26H26N2O2S [430.57]: C 72.53, H 
6.09, N 6.51; found: C 72.87, H 5.99, N 6.61. 
N-(2-(1H-indol-3-yl)-2-phenylethyl)-4-methylbenzenesulfonamide (3k). Procedure A was 
followed using 1H-indole (1k) (51.4 mg, 0.3 mmol), 2-phenyl-1-tosylaziridine (2a) (90.2 mg, 0.33 
mmol) and [Au(JohnPhos)(NTf2)] (11.6 mg, 0.015 mmol) in DCE (2 mL). Purification of the 
crude by column chromatography (Hex/EtOAc 8:2) yielded 3k (100 mg, 83%) as a white solid 
(m.p.:185-188°C). 1H-NMR (200 MHz, DMSO-d6): δ 10.86 (s, 1H), 7.62 (dd, J = 8.1, 1.5 Hz, 
2H), 7.39-7.05 (m, 10H), 7.00 (t, J = 8.2 Hz, 1H), 6.85 (t, J = 7.9 Hz, 1H), 4.27 (t, J = 7.7 Hz, 1H), 
3.35-3.19 (m, 2H), 2.32 (s, 3H). 13C-NMR (50 MHz, DMSO-d6): δ 143.6 (C), 143.1 (C), 138.3 
(C), 136.9 (C), 130.2 (2 x CH), 128.9 (2 x CH), 128.7(2 x CH), 127.2 (2 x CH), 127.1 (C), 126.8 
(CH), 122.8 (CH), 121.7 (CH), 119.0 (CH), 116.1 (C), 112.1 (CH), 48.2 (CH2), 43.3 (CH), 21.6 
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(CH3). ESI-MS m/z 391 [M – H
+, 100]. Calcd. for C23H22N2O2S [390.50]: C 70.74, H 5.68, N 
7.17; found C 70.99, H 5.75, N 7.01. 
(S)-N-(2-(1H-indol-3-yl)-2-phenylethyl)-4-methylbenzenesulfonamide ((S)3k). Procedure A 
was followed using (R)-2-phenyl-1-tosylaziridine ((R)2a). (S)3k was obtained in 85% yield and 
97% ee. (S)3k was analyzed via chiral-HPLC in comparison with racemic 3k, see supporting 
information (HPLC section) for details. 
4-methyl-N-(2-phenyl-2-(2-phenyl-6-(trifluoromethyl)-1H-indol-3-
yl)ethyl)benzenesulfonamide (3l). Procedure A was followed using 2-phenyl-6-(trifluoromethyl)-
1H-indole (1l) (78.4 mg, 0.3 mmol), 2-phenyl-1-tosylaziridine (2a) (90.2 mg, 0.33 mmol) and 
[Au(JohnPhos)(NTf2)] (11.6 mg, 0.015 mmol) in DCE (2 mL). Purification of the crude by 
column chromatography (Hex/EtOAc 8:2) yielded 3l (156 mg, 97%) as a white solid (m.p.: 201-
203 °C). 1H-NMR (200 MHz, CDCl3): δ 8.64 (s, 1H), 7.68 (s, 1H), 7.46-7.34 (m, 7H), 7.32-6.99 
(m, 9H), 4.49 (dd, J = 10.7, 6.0 Hz, 1H), 4.13 (m, 1H), 3.69 (m, 2H), 2.40 (s, 3H). 13C-NMR (50 
MHz, CDCl3): δ 143.6 (C), 141.2 (C), 140.6 (C), 136.4 (C), 135.3 (C), 131.6 (C), 129.8 (2 x CH), 
129.5 (C), 129.2 (2 x CH), 129.1 (CH), 129.0 (2 x CH), 128.9 (2 x CH), 127.8 (2 x CH), 127.1 (2 
x CH), 125.2 (q, J = 271 Hz, C), 124.6 (q, J = 32 Hz, C), 120.4 (CH), 116.9 (q, J = 3.5 Hz, CH), 
110.5 (C), 109.1 (q, J = 4.3 Hz, CH), 46.8 (CH2), 42.2 (CH), 21.6 (CH3). ESI-MS m/z 533 [M – 
H+, 100]. Calcd. for C30H25F3N2O2S [534.60]: C 67.40, H 4.71, N 5.24; found: C 67.76; H 4.80, N 
5.31. 
N-(2-(6-(diethylamino)-1H-indol-3-yl)ethyl)-4-methylbenzenesulfonamide (3m). Procedure A 
was followed using N,N-diethyl-1H-indol-6-amine (1m) (56.50 mg, 0.3 mmol), 2-phenyl-1-
tosylaziridine (90.2 mg, 0.33 mmol) (2a) and [Au(JohnPhos)(NTf2)] (11.6 mg, 0.015 mmol) in 
DCE (2 mL). Purification of the crude by column chromatography (Hex/EtOAc 8:2) yielded 3m 
(41 mg, 30%) as a white solid (m.p.: 54-56°C). 1H NMR (C6D6, 200 MHz): δ 7.45 (d, J = 8.4 Hz, 
1H), 7.36 (d, J = 8.1 Hz, 2H), 7.19-7.12 (m, 3H), 6.98-6.89 (m, 4H), 6.58 (d, J = 8.1 Hz, 2H), 
6.26-6.22 (m, 2H), 5.41 (t, J = 7.0 Hz, 1H), 4.73 (bs, 1H), 3.94-3.84 (m, 1H), 3.47-3.36 (m, 1H), 
2.77 (q, J = 7.0 Hz, 4H), 1.83 (s, 3H), 0.86 (t, J = 7.0 Hz, 6H). 13C NMR (C6D6, 50 MHz): δ 145.0 
(C), 142.3 (C), 140.9 (C),137.3 (C), 135.1 (C), 129.3 (2 x CH), 129.0 (2 x CH), 127.1 (2 x CH), 
126.8 (C), 126.7 (2 x CH), 124.6 (CH), 121.6 (C), 120.4 (CH), 116.1 (CH), 102.3 (CH), 49.5 
(CH2), 45.8 (2 x CH2), 40.7 (CH), 20.9 (CH3), 12.8 (2 x CH3). 1 CHar is missing, probably 
overlapping. ESI-MS m/z 484 [M + Na+, 100], 462 [M + H+, 60]. Calcd for C27H31N3O2S: C 
70.25, H 6.77, N 9.10; found C 70.15, H 6.53, N 9.07. 
Ethyl 3-(2-(4-methylphenylsulfonamido)-1-phenylethyl)-1H-indole-2-carboxylate (3n). 
Procedure A was followed using ethyl 1H-indole-2-carboxylate (1n) (56.7 mg, 0.3 mmol), 2-
phenyl-1-tosylaziridine (2a) (90.2 mg, 0.33 mmol) and [Au(JohnPhos)(NTf2)] (11.6 mg, 0.015 
mmol) in DCE (2 mL). Purification of the crude by column chromatography (Hex/EtOAc 8:2) 
yielded 3n (75 mg, 54%) as a white solid (m.p.: 175-177 °C). 1H-NMR (200 MHz, 
CDCl3): δ 9.19 (s, 1H), 7.58 (d, J = 8.3 Hz, 2H), 7.38 (d, J = 8.2 Hz, 1H), 7.32 – 7.10 (m, 9H), 
6.91 (t, J = 7.0 Hz, 1H), 5.39 (dd, J = 10.0, 6.1 Hz, 1H), 4.88 (m, 1H), 4.28 (q, J = 7.1 Hz, 2H), 
4.00-3.70 (m, 2H), 2.39 (s, 3H), 1.37 (t, J = 7.1 Hz, 3H). 13C-NMR (50 MHz, CDCl3): δ 162.3 
(C), 143.4 (C), 141.1 (C), 136.9 (C), 136.4 (C), 129.7 (2 x CH), 128.7 (2 x CH), 127.9 (2 x CH), 
127.2 (2 x CH), 126.9 (CH), 126.5 (C), 125.7 (CH), 124.8 (C), 122.0 (CH), 121.9 (C), 120.8 (CH), 
112.5 (CH), 61.6 (CH2), 46.6 (CH2), 41.6 (CH), 21.7 (CH3), 14.5 (CH3). ESI-MS m/z 461 [M – 
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H+, 100]. Calcd. for C26H26N2O4S [462.56]: C 67.51, H 5.67, N 6.06; found: 67.88, H. 5.52, N. 
6.19. 
Ethyl 5-fluoro-3-(2-(4-methylphenylsulfonamido)-1-phenylethyl)-1H-indole-2-carboxylate 
(3o). Procedure A was followed using ethyl 5-fluoro-1H-indole-2-carboxylate (1o) (62.2 mg, 0.3 
mmol), 2-phenyl-1-tosylaziridine (2a) (90.2 mg, 0.33 mmol) and [Au(JohnPhos)(NTf2)] (11.6 mg, 
0.015 mmol) in DCE (2 mL). Purification of the crude by column chromatography (Hex/EtOAc 
8:2) yielded 3o (75 mg, 54%) as a white solid (m.p.: 125-127 °C). 1H-NMR (200 MHz, 
CDCl3): δ 9.27 (s, 1H), 7.79 (d, J = 8.3 Hz, 1H), 7.57 (d, J = 8.3 Hz, 2H), 7.35-7.12 (m, 7H), 6.99 
(td, J = 9.0, 2.4 Hz, 1H), 6.78 (dd, J = 9.9, 2.3 Hz, 1H), 5.33 (dd, J = 5.9, 10.4 Hz, 1H), 4.90 (m, 
1H), 4.29 (q, J = 7.1 Hz, 2H), 3.89 (dt, J = 12.7, 6.4 Hz, 1H), 3.69 (td, J = 11.8, 4.6 Hz, 1H), 2.40 
(s, 3H), 1.37 (t, J = 7.1 Hz, 3H). 13C NMR (50 MHz, CDCl3): δ 162.0 (C), 157.8 (d, JC-F = 237 
Hz, C), 143.5 (C), 140.7 (C), 136.7 (C), 133.0 (C), 129.8 (2 x CH), 128.8 (2 x CH), 127.8 (2 x 
CH), 127.1 (2 x CH), 127.0 (CH), 126.4 (C), 121.7 (d, JC-F  = 5.5 Hz, C), 114.9 (d, JC-F  = 27 Hz, 
CH), 113.5 (d, JC-F  = 9.4 Hz, CH), 106.3 (d, JC-F  = 24 Hz, CH), 61.7 (CH2), 46.2 (CH2), 41.3 
(CH), 21.7 (CH3), 14.5 (CH3). ESI-MS m/z 479 [M – H
+, 100]. Calcd. for C26H25FN2O4S 
[480.55]: C 64.98, H 5.24, N 5.83; found: C 64.72, H 5.38, N 5.91. 
4-methyl-N-(2-(2-phenyl-1H-indol-3-yl)ethyl)benzenesulfonamide (3p). Procedure A was 
followed using 2-phenyl-1H-indole (1a) (58 mg, 0.3 mmol), 1-tosylaziridine (2b) (71 mg, 0.36 
mmol, 1.2 equiv.) and [Au(JohnPhos)(NTf2)] (11.6 mg, 0.015 mmol) in DCE (2 mL). Purification 
of the crude by column chromatography (Hex/EtOAc 8:2) yielded 3p (77 mg, 66%) as a white 
solid (m.p.: 129-130 °C). 1H-NMR (200 MHz, CDCl3): δ 8.16 (s, 1H), 7.58 (d, J = 8.3 Hz, 2H), 
7.51-7.33 (m, 7H), 7.27-7.03 (m, 4H), 4.40 (t, J = 6.0 Hz, 1H), 3.26 (m, 2H), 3.07 (m, 2H), 2.39 
(s, 3H). 13C-NMR (50 MHz, CDCl3): δ 143.4 (C), 137.1 (C), 136.1(C), 135.9 (C), 132.8 (C), 
129.8 (2 x CH), 129.2 (2 x CH), 128.8 (C), 128.4 (2 x CH), 128.2 (CH), 127.2 (2 x CH), 122.8 
(CH), 120.2 (CH), 119.0 (CH), 111.2 (CH), 108.6 (C), 43.4 (CH2), 25.2 (CH2), 21.7 (CH3). ESI-
MS m/z 389 [M – H+, 100]. Calcd. for C23H22N2O2S [390.50]: C 70.74, H 5.68, N 7.17; found C 
70.95, H 5.56, N 7.01. 
N-(2-(2-(4-isopropoxyphenyl)-1H-indol-3-yl)ethyl)-4-methylbenzenesulfonamide (3q). 
Procedure A was followed using 2-(4-isopropoxyphenyl)-1H-indole (1c) (75.3 mg, 0.3 mmol), 1-
tosylaziridine (2b) (71 mg, 0.36 mmol, 1.2 equiv.) and [Au(JohnPhos)(NTf2)] (11.6 mg, 0.015 
mmol) in DCE (2 mL). Purification of the crude by column chromatography (Hex/EtOAc 8:2) 
yielded 3q (96 mg, 71%) as a white solid (m.p.: 54-55 °C). 1H-NMR (200 MHz, CDCl3): δ 8.12 
(s, 1H), 7.57 (d, J = 8.4 Hz, 2H), 7.44-7.31 (m, 4H), 7.22-7.01 (m, 4H), 6.93 (d, J = 8.9 Hz, 2H), 
4.59 (hept, J = 6.0 Hz, 1H), 4.41 (t, J = 6.1 Hz, 1H), 3.26 (m, 2H), 3.04 (m, 2H), 2.39 (s, 3H), 1.38 
(d, J = 6.1 Hz, 6H). 13C-NMR (50 MHz, CDCl3): δ 158.1 (C), 143.3 (C), 137.1 (C), 136.1 (C), 
135.9 (C), 129.8 (2 x CH), 129.6 (2 x CH), 128.9 (C), 127.2 (2 x CH), 124.8 (C), 122.4 (CH), 
120.1 (CH), 118.7 (CH), 116.4 (2 x CH), 111.1 (CH), 107.7 (C), 70.3 (CH), 43.4 (CH2), 25.2 
(CH2), 22.3 (CH3), 21.7 (CH3). ESI-MS m/z 447 [M – H
+, 100]. Calcd. for C26H28N2O3S [448.58]: 
C 69.62, H 6.29, N 6.25; found C 69.86, H 6.32, N 6.18. 
N-(2-(2-(3-acetylphenyl)-1H-indol-3-yl)ethyl)-4-methylbenzenesulfonamide (3r). Procedure A 
was followed using 1-(3-(1H-indol-2-yl)phenyl)ethanone (1d) (70.6 mg, 0.3 mmol), 1-
tosylaziridine (2b) (71 mg, 0.36 mmol, 1.2 equiv.) and [Au(JohnPhos)(NTf2)] (11.6 mg, 0.015 
mmol) in DCE (2 mL). Purification of the crude by column chromatography (Hex/EtOAc 7:3) 
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yielded 3r (80 mg, 62%) as a yellowish solid (m.p.: 52.5-54 °C). 1H-NMR (200 MHz, 
CDCl3): δ 8.59 (s, 1H), 8.06 (m, 1H), 7.86 (d, J = 7.5 Hz, 1H), 7.73 (d, J = 7.8 Hz, 1H), 7.62-7.30 
(m, 5H), 7.27-7.01 (m, 4H), 4.80 (t, J = 6.1 Hz, 1H), 3.27 (m, 2H), 3.08 (m, 2H), 2.58 (s, 3H), 
2.37 (s, 3H). 13C-NMR (50 MHz, CDCl3): δ 198.4 (C), 143.5 (C), 137.8 (C), 137.1 (C), 136.3 (C), 
134.7 (C), 133.3 (C), 132.8 (CH), 129.8 (2 x CH), 129.5 (CH), 128.7 (C), 127.9 (CH), 127.8 (CH), 
127.2 (2 x CH), 123.1 (CH), 120.3 (CH), 119.1 (CH), 111.5 (CH), 109.3 (C), 43.5 (CH2), 26.9 
(CH3), 25.5 (CH2), 21.7 (CH3). ESI-MS m/z 431 [M – H
+, 100]. Calcd. for C25H24N2O3S [432.53]: 
C 69.42, H 5.59, N 6.48; found C 69.83, H 5.47, N 6.22. 
4-methyl-N-(2-(2-methyl-1H-indol-3-yl)ethyl)benzenesulfonamide (3s). Procedure A was 
followed using 2-methyl-1H-indole (1e) (39.4 mg, 0.3 mmol), 1-tosylaziridine (2b) (71 mg, 0.36 
mmol, 1.2 equiv.) and [Au(JohnPhos)(NTf2)] (11.6 mg, 0.015 mmol) in DCE (2 mL). Purification 
of the crude by column chromatography (Hex/EtOAc 8:2) yielded 3s (70 mg, 71%) as a white 
wax. 1H-NMR (200 MHz, CDCl3): δ 7.82 (s, 1H), 7.62 (d, J = 8.3 Hz, 2H), 7.33-7.16 (m, 4H), 
7.14-6.96 (m, 2H), 4.31 (t, J = 6.2 Hz, 1H), 3.22 (m, 2H), 2.90 (m, 2H), 2.40 (s, 3H), 2.35 (s, 3H). 
13
C-NMR (50 MHz, CDCl3): δ 143.5 (C), 137.1 (C), 135.6 (C), 132.7 (C), 129.8 (2 x CH), 128.4 
(C), 127.2 (2 x CH), 121.4 (CH), 119.6 (CH), 117.8 (CH), 110.7(CH), 107.3 (C), 43.4 (CH2), 24.9 
(CH2), 21.7 (CH3), 11.8 (CH3). ESI-MS m/z 327 [M – H
+, 65]. Calcd. for C18H20N2O2S [328.43]: 
C 65.83, H 6.14, N 8.53; found C 66.11, H 6.00, N 8.77. 
N-(2-(1H-indol-3-yl)ethyl)-4-methylbenzenesulfonamide (3t). Procedure A was followed using 
1H-indole (1k) (35.1 mg, 0.3 mmol), 1-tosylaziridine (2b) (71 mg, 0.36 mmol, 1.2 equiv.) and 
[Au(JohnPhos)(NTf2)] (11.6 mg, 0.015 mmol) in DCE (2 mL). Purification of the crude by 
column chromatography (Hex/EtOAc 9:1) yielded 3t (65 mg, 69%) as a white wax. 1H-NMR 
(200 MHz, CDCl3): δ 8.03 (s, 1H), 7.64 (d, J = 8.3 Hz, 3H), 7.45-6.92 (m, 7H), 4.38 (t, J = 5.9 Hz, 
1H), 3.28 (m, 2H), 2.93 (m, 2H), 2.40 (s, 3H). 13C-NMR (50 MHz, CDCl3): δ 143.5 (C), 137.1 
(C), 136.7 (C), 129.8 (2 x CH), 127.2 (2 x CH), 122.9 (CH), 122.4 (CH), 119.7 (CH), 118.7 (CH), 
111.8 (C), 111.6 (CH), 43.3 (CH2), 25.7 (CH2), 21.7 (CH3). ESI-MS m/z 313 [M – H
+, 100]. 
Calcd. for C17H18N2O2S [314.40]: C 64.94, H 5.77, N 8.91; found C 65.19, H 5.83, N 8.87. 
benzyl (2-(2-phenyl-1H-indol-3-yl)ethyl)carbamate (3x). Procedure A was followed using 2-
phenyl-1H-indole (1a) (58 mg, 0.3 mmol), benzyl aziridine-1-carboxylate (2d) (64 mg, 0.36 
mmol, 1.2 equiv.) and [Au(JohnPhos)(NTf2)] (11.6 mg, 0.015 mmol) in DCE (2 mL). Purification 
of the crude by column chromatography (Hex/EtOAc 9:1) yielded 3x (63 mg, 57%) as a white 
solid (m.p.: 46-48 °C). 1H NMR (300 MHz, CDCl3): δ 8.26 (s, 1H), 7.69-7.12 (m, 14H), 5.05 (s, 
1H), 4.84 (t, J = 6.0 Hz, 1H), 3.53 (q, J = 6.8 Hz, 2H), 3.13 (t, J = 7.1 Hz, 2H). 13C NMR (75 
MHz, CDCl3): δ 156.6 (C), 136.9 (C), 136.1 (C), 135.7 (C), 133.1 (C), 129.2 (C), 129.2 (2 x CH), 
128.7 (CH), 128.3 (4 x CH), 128.2 (2 x CH), 128.1 (CH), 122.7 (CH), 120.1 (CH), 119.3 (CH), 
111.2 (CH), 109.8 (C), 66.7 (CH2), 41.8 (CH2), 25.3 (CH2). ESI-MS m/z 393 [M + Na
+, 75], 371 
[M + H+, 100]. Calcd. for C24H22N2O2 [370.44]: C 77.81, H 5.99, N 7.56; found C 77.69, H 5.87, 
N 7.68. 
4-methyl-N-(2-(2-phenyl-1H-indol-3-yl)cyclohexyl)benzenesulfonamide (3y). Procedure A was 
followed using 2-phenyl-1H-indole (1a) (58 mg, 0.3 mmol), 7-tosyl-7-azabicyclo[4.1.0]heptane 
(2e) (91 mg, 0.36 mmol, 1.2 equiv.) and [Au(JohnPhos)(NTf2)] (11.6 mg, 0.015 mmol) in DCE (2 
mL). Purification of the crude by column chromatography (Hex/EtOAc 8:2) yielded 3y (35 mg, 
26%) as a white wax. 1H NMR (300 MHz, CDCl3): δ 8.02 (s, 1H), 7.51-7.39 (m, 5H), 7.29-7.18 
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(m, 2H), 7.15-7.08 (m, 3H), 6.84-6.77 (m, 3H), 4.15 (m, 1H), 3.43 (m, 1H), 2.83 (ddd, J = 12.2, 
10.8, 4.1, 1H), 2.52 (m, 1H), 2.30 (s, 3H), 1.88 (m, 3H), 1.30 (m, 4H). 13C NMR (75 MHz, 
CDCl3): δ 142.6 (C), 136.4 (2 x C), 136.0 (C), 132.7 (C), 129.3 (2 x CH), 129.2 (2 x CH), 129.0 (2 
x CH), 128.6 (CH), 126.6 (2 x CH), 122.1 (CH), 120.3 (CH), 119.7 (CH), 112.5 (C), 111.3 (CH), 
56.3 (CH), 41.7 (CH), 35.0 (CH2), 32.5 (CH2), 26.2 (CH2), 25.3 (CH2), 21.8 (CH3) (one 
quaternary carbon is missing, probably overlapped with one negative signal, CH). ESI-MS m/z 
444 [M + H+, 100]. Calcd. for C27H28N2O2S [444.59]: C 72.94, H 6.35, N 6.30; found C 72.86, H 
6.12, N 6.41. 
 
Representative procedures for the ring opening reactions of 2-methyl-N-tosyl aziridine (2c 
and (S)2c) – see table 2 for details. 
 
Table 2, entries 1, 2, 3 general procedure. To a N2-flushed solution of indole 1a,c,e (1.0 equiv.) 
and 2-methyl-N-tosyl aziridine (2c) (1.1 equiv.) in DCE (0.15 M), [Au(JohnPhos)(NTf2)] (5 
mol%) was added and the mixture was stirred at 80 °C for 24 h. Solvent was then removed in 
vacuum and the residue was purified by column chromatography (SiO2) to yield the corresponding 
product 3u-w/3’u-w as inseparable mixtures. 
4-methyl-N-(2-(2-phenyl-1H-indol-3-yl)propyl)benzenesulfonamide (3u) and 4-methyl-N-(1-
(2-phenyl-1H-indol-3-yl)propan-2-yl)benzenesulfonamide (3’u). General procedure was 
followed using 1H-indole 1a (39.0 mg, 0.2 mmol), aziridine 2c (46.5 mg, 0.22 mmol) and 
[Au(JohnPhos)(NTf2)] (7.75 mg, 0.01 mmol) in DCE (2 mL). Purification of the crude by column 
chromatography (Hex/EtOAc 8:2) yielded 3u/3’u (79.3 mg, 98%) in 2:1 ratio as a white solid. 
Ratio and identity of the two regioisomers were established via 1D and 2D NMR analysis. See 
copy of original spectra enclosed in the supporting information. ESI-MS m/z 403 [M – H+, 100]. 
Reported data are in agreement with those reported in literature.3i 
N-(2-(2-(4-isopropoxyphenyl)-1H-indol-3-yl)propyl)-4-methylbenzenesulfonamide (3v) and 
N-(1-(2-(4-isopropoxyphenyl)-1H-indol-3-yl)propan-2-yl)-4-methylbenzenesulfonamide (3’v). 
General procedure was followed using 1H-indole 1c (75.4 mg, 0.3 mmol), aziridine 2c (69.7 mg, 
0.33 mmol) and [Au(JohnPhos)(NTf2)] (11.6 mg, 0.015 mmol) in DCE (2 mL). Purification of the 
crude by column chromatography (Hex/EtOAc 8:2) yielded 3v/3’v (120 mg, 86%) in 2:1 ratio as a 
pink solid. Ratio and identity of the two regioisomers were established by analogy with 3u/3’u via 
1H NMR analysis. See copy of original spectra enclosed in the supporting information. ESI-MS 
m/z 461 [M – H+, 100]. 
4-methyl-N-(2-(2-methyl-1H-indol-3-yl)propyl)benzenesulfonamide (3w) and 4-methyl-N-(1-
(2-methyl-1H-indol-3-yl)propan-2-yl)benzenesulfonamide (3’w). General procedure was 
followed using 1H-indole 1e (39.5 mg, 0.3 mmol), aziridine 2c (69.7 mg, 0.33 mmol) and 
[Au(JohnPhos)(NTf2)] (11.6 mg, 0.015 mmol) in DCE (2 mL). Purification of the crude by 
column chromatography (Hex/EtOAc 8:2) yielded 3w/3’w (94.4 mg, 92%) in 2:1 ratio as a pink 
thick oil. Ratio and identity of the two regioisomers were established by analogy with 3u/3’u via 
1H NMR analysis. See copy of original spectra enclosed in the supporting information. ESI-MS 
m/z 341 [M – H+, 100]. 
 
Page 20 of 26Organic & Biomolecular Chemistry
O
rg
an
ic
&
B
io
m
ol
ec
ul
ar
C
he
m
is
tr
y
A
cc
ep
te
d
M
an
us
cr
ip
t
Pu
bl
ish
ed
 o
n 
25
 M
ay
 2
01
6.
 D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ita
 S
tu
di
 d
i M
ila
no
 o
n 
25
/0
5/
20
16
 1
1:
34
:2
4.
 
View Article Online
DOI: 10.1039/C6OB00672H
Table 2, entry 4. To a solution of 1H-indole 1a (58.0 mg, 0.3 mmol) and aziridine 2c (42.3 mg, 
0.2 mmol) in DCM (1 mL) boron trifluoride etherate (0.04 mL, 0.3 mmol) was added at room 
temperature over a period of 10 min. The solution was stirred for 24 h. and quenched with 5% 
aqueous NaHCO3 solution (1 mL). The two phases were separated and aqueous layer was 
extracted with DCM (2 x 1mL). The combined organic layers were dried over Na2SO4, filtered 
and concentrated in vacuum. Purification by column chromatography (Hex/EtOAc 8:2) yielded 3u 
and 3’u (43 mg, 55%) as inseparable mixture in 12:1 ratio as a white solid. Reported data refers to 
major isomer and are in agreement with those reported in ref. 3i. 1H-NMR (200 MHz, 
CDCl3): δ 8.10 (s, 1H), 7.49-7.30 (m, 9H), 7.26-7.15 (m, 3H), 6.99 (t, J = 7.3 Hz, 1H), 4.18 (d, J = 
7.1 Hz, 1H), 3.32 (m, 3H), 2.40 (s, 3H), 1.39 (d, J = 5.9 Hz, 3H).13C NMR (50 MHz, 
CDCl3): δ 143.2 (C), 136.7 (C), 136.5 (2 x C), 132.8 (C), 129.7 (2 x CH), 129.1 (2 x CH), 129.0 (2 
x CH), 128.4 (CH), 127.1 (2 x CH), 126.7 (C), 122.5 (CH), 120.0 (CH), 119.9 (CH), 112.9 (C), 
111.5 (CH), 48.1 (CH2), 31.8 (CH), 21.7 (CH3), 19.0 (CH3). ESI-MS m/z 427 [M + Na
+, 100]. 
 
Table 2, entry 12. To a N2-flushed solution of AuCl (2.3 mg, 0.01 mmol) and AgSbF6 (3.4 mg, 
0.01 mmol) in DCE (1.33 mL), indole 1a (77.3 mg, 0.4 mmol) and aziridine 2c (42.3 mg, 0.20 
mmol) were added and the mixture was stirred for 24 h at 80 °C. Solvent was then removed in 
vacuum and the residue was purified by column chromatography (Hex/EtOAc 8:2) yielding 
3u/3’u (51 mg, 70%) as inseparable mixture in 7:1 ratio as a white solid. Ratio and identity of the 
two regioisomers were established via 1H NMR analysis and are in agreement with those reported 
in ref. 12. See the enclosed copy of original spectra. The same reaction was performed using (S)-2-
methyl-1-tosylaziridine ((S)2c). The purified reaction mixture was analyzed via chiral-HPLC, see 
supporting information (HPLC section) for details. 
 
Preparation and characterization data for compounds (±)4a-d and (±)4’a-c 
 
(±)-3a,8-dimethyl-3-phenyl-1-tosyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indole ((±)4a and 
(±)4’a). Procedure A was followed using 1,3-dimethyl-indole (1p) (87.1 mg, 0.6 mmol), aziridine 
2a (197 mg, 0.72 mmol) and [Au(JohnPhos)(NTf2)] (23.3 mg, 0.03 mmol) in DCE (4 mL). 
Purification of the crude by column chromatography (Hex/DCM 1:1) yielded progressively (±)4a 
and (±)4’a (170 mg, overall yield 68%, ratio 60:40 ) as white solids (m.p.: (±)4a 115-117.2 °C; 
(±)4’a 173-176 °C). (±)4a16: 1H NMR (300 MHz, CDCl3): δ 7.86 (d, J = 8.3 Hz, 2H), 7.42 (d, J = 
8.0 Hz, 2H), 7.29-7.23 (m, 3H), 7.05 (dt, J = 7.7, 1.3 Hz, 1H), 6.85 (d, J = 6.2, 2H), 6.39 (d, J = 
7.8 Hz, 1H), 6.31 (t, J = 7.4 Hz, 1H), 5.60 (d, J = 7.4 Hz, 1H), 5.40 (s, 1H), 3.80 (dd, J = 12.2, 6.5 
Hz, 1H), 3.42 (t, J = 12.4 Hz, 1H), 3.07 (s, 3H), 2.76 (dd, J = 12.6, 6.5 Hz, 1H), 2.50 (s, 3H), 1.31 
(s, 3H). 13C NMR (75 MHz, CDCl3): δ 151.2 (C), 144.2 (C), 137.6 (C), 136.1 (C), 130.3 (2 x 
CH), 129.2 (2 x CH), 129.0 (C), 128.8 (CH), 128.3 (2 x CH), 127.9 (CH), 127.7 (2 x CH), 125.8 
(CH), 116.8 (CH), 105.4 (CH), 91.5 (CH), 57.1 (C), 55.4 (CH), 51.6 (CH2), 31.7 (CH3), 26.4 
(CH3), 22.0 (CH3). ESI(+)-MS (m/z %): 441 (100) [M + Na]
+. Calcd. for C25H26N2O2S [418.56]: 
C 71.74, H 6.26, N 6.69; found C.71.92, H 6.16, N 6.85. (±)4’a16b: 1H NMR (300 MHz, 
CDCl3): δ 7.90 (d, J = 8.2 Hz, 2H), 7.42 (d, J = 8.1 Hz, 2H), 7.38-7.24 (m, 3H), 7.19 (t, J = 7.6 
Hz, 1H), 6.96 (dd, J = 6.6, 2.9 Hz, 2H), 6.67 (t, J = 7.4 Hz, 1H), 6.56 (dd, J = 7.1, 3.5 Hz, 2H), 
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5.10 (s, 1H), 3.89-3.76 (m, 2H), 3.61 (dd, J = 11.0, 8.0 Hz, 1H), 3.06 (s, 3H), 2.50 (s, 3H), 0.53 (s, 
3H). 13C NMR (75 MHz, CDCl3): δ 149.5 (C), 144.4 (C), 135.7 (C), 135.5 (C), 133.0 (C), 130.2 
(2 x CH), 129.1 (2 x CH), 129.0 (CH), 128.5 (2 x CH), 128.2 (2 x CH), 127.8 (CH), 122.7 (CH), 
118.2 (CH), 107.9 (CH), 94.8 (CH), 54.5 (C), 52.9 (CH2), 52.4 (CH), 33.2 (CH3), 22.0 (CH3), 16.9 
(CH3). ESI-MS m/z 419 [M + H
+, 100]. Calcd. for C25H26N2O2S [418.56]: C 71.74, H 6.26, N 
6.69; found: C 71.88, H 6.02, N 6.98. 
8-benzyl-3a-methyl-3-phenyl-1-tosyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indole ((±)4b and 
(±)4’b). Procedure A was followed using indole 1p (132.7 mg, 0.6 mmol), aziridine 2a (196.8 mg, 
0.72 mmol) and [Au(JohnPhos)(NTf2)] (23.3 mg, 0.03 mmol) in DCE (4 mL). Purification of the 
crude by column chromatography (Hex/EtOAc 9:1) yielded (±)4b and (±)4’b as inseparable 
mixture (187 mg, overall yield 63%, ratio 60:40, white solid). (±)4b13,14/(±)4’b: 1H-NMR (300 
MHz, CDCl3): by comparison with NMR data in ref 16b, signals marked in blue and red can be 
attributed to (±)4b and (±)4’b, respectively. Signals in black are superimposed hydrogens. δ 7.76 
(m, 4H), 7.46-7.20 (m, 20H), 7.08 (dt, J = 1.6, 7.5 Hz, 1H), 7.03-6.94 (m, 3H), 6.87 (dd, J = 1.6, 
7.7 Hz, 2H), 6.65 (t, J = 7.2 Hz, 1H), 6.60 (dd, J = 1.6, 7.3 Hz, 1H), 6.42 (d, J = 7.9 Hz, 1H), 6.35 
(d, J = 7.9 Hz, 1H), 6.30 (dt, J = 0.8, 7.4 Hz, 1H), 5.60 (dd, J = 1.1, 7.4 Hz, 1H), 5.52 (s, 1H), 5.45 
(s, 1H), 4.77 (AB, J = 16.2 Hz, 2H), 4.75 (AB, J = 16.5 Hz, 2H), 3.81-3.90 (m, 3H), 3.53 (t, J = 
9.3 Hz, 1H), 3.53 (t, J = 12.6 Hz, 1H), 2.79 (dd, J = 12.7, 6.4 Hz, 1H), 2.48 (s, 3H), 2.46 (s, 3H), 
1.27 (s, 3H), 0.58 (s, 3H). 13C-NMR (75 MHz, CDCl3): δ 150.3, 148.7, 144.2, 144.1, 139.2, 138.9, 
137.3, 136.00, 135.7, 135.2, 132.9, 130.1, 130.0, 129.1 129.0, 128.8, 128.7, 128.7, 128.6, 128.4, 
128.2, 128.0, 127.7, 127.6, 127.6, 127.4, 127.2, 127.0, 126.0, 122.5, 117.9, 116.7, 108.0, 105.6, 
92.5, 90.1, 57.1, 55.5, 54.8, 52.8, 52.7, 51.4, 49.9, 48.3, 29.9, 26.66, 21.9, 17.0. ESI-MS m/z 495 
[M + H+, 100]. 
(±)-3a,8a-dimethyl-3-phenyl-1-tosyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indole ((±)4c and 
(±)4’c). Procedure A was followed using 2,3-dimethyl-1H-indole (1r) (43.6 mg, 0.3 mmol), 
aziridine 2a (90.2 mg, 0.33.) and [Au(JohnPhos)(NTf2)] (11.6 mg, 0.015 mmol) in DCE (2 mL). 
Purification of the crude by column chromatography (Hex/EtOAc 98:2-9:1-8:2) yielded 
progressively (±)4’c and (±)4c (69 mg, overall yield 55%, ratio (±)4c/(±)4’c 70:30) as white 
solids (m.p: (±)4c 177-179 °C; (±)4’c 145-147 °C). (±)4c: 1H-NMR (300 MHz, CDCl3): δ 7.72 
(d, J = 8.1 Hz, 2H), 7.41-6.95 (m, 8H), 6.56 (t, J = 7.8 Hz, 1H), 6.46 (t, J = 7.3 Hz, 1H), 5.92 (d, J 
= 7.4 Hz, 1H), 5.42 (bs, 1H), 3.58-3.32 (m, 3H), 2.39 (s, 3H), 1.84 (s, 3H), 1.22 (s, 3H). 13C-NMR 
(75 MHz, CDCl3): δ 148.2 (C), 143.3 (C), 139.1 (C), 137.6 (C), 135.6 (C), 129.7 (2 x CH), 129.6 
(2 x CH), 128.3 (2 x CH), 127.9 (CH), 127.7 (CH), 127.3 (2 x CH), 126.1 (CH), 118.4 (CH), 
109.2 (CH), 91.9 (C), 59.5 (C), 51.4 (CH), 50.6 (CH2), 23.5 (CH3), 22.7 (CH3), 21.7 (CH3). ESI-
MS m/z 419 [M +H+, 100]. Calcd. for C25H26N2O2S [418.56]: C 71.74, H 6.26, N 6.69; found: C 
71.95, H 6.02, N 6.81. (±)4’c: 1H-NMR (300 MHz, CDCl3): δ 7.80 (d, J = 8.3 Hz, 2H), 7.32-7.23 
(m, 5H), 7.15-7.08 (m, 2H), 7.06 (dd, J = 7.6, 1.1 Hz, 1H), 6.99 (d, J = 6.8 Hz, 1H), 6.76 (dt, J = 
7.4, 0.8 Hz, 1H), 6.58 (d, J = 7.8 Hz, 1H), 5.26 (bs, 1H), 3.70 (dd, J = 7.5, 2.1 Hz, 1H), 3.47 (m, 
2H), 2.43 (s, 3H), 1.72 (s, 3H), 0.93 (s, 3H). 13C-NMR (75 MHz, CDCl3): δ 146.9 (C), 143.6 (C), 
139.3 (C), 137.3 (C), 135.0 (C), 129.9 (2 x CH), 129.1 (2 x CH), 128.7 (CH), 128.5 (2 x CH), 
127.9 (2 x CH), 127.5 (CH), 122.8 (CH), 119.4 (CH), 109.5 (CH), 92.3 (C), 59.8 (C), 52.6 (CH2), 
51.6 (CH), 24.1 (CH3), 21.9 (CH3), 19.7 (CH3). ESI-MS m/z 419 [M + H
+, 100]. Calcd. for 
C25H26N2O2S [418.56]: C 71.74, H 6.26, N 6.69; found: C 71.90, H 6.11, N 6.58. 
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Reactions between indoles 1p-q and aziridine (R)2a. The reactions between indoles 1p-q and 
aziridine (R)2a were performed as reported above for the reactions with racemic 2a. Crude 
reaction mixtures were purified through a short pad of silica gel giving rise to pure mixtures of 
4a/4’a and 4b/4’b which were evaluated via chiral HPLC analysis, in comparison with racemic 
(±)4a/(±)4’a and (±)4b/(±)4’b, respectively, see supporting information (HPLC section) for 
details. 
(±)-(3a,8a-cis)-3a,8-dimethyl-1-tosyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indole ((±)4d). 
Entry 7, scheme 6. In a nitrogen flushed vial a solution of aziridine 2b (39.5 mg, 0.2 mmol) and 
[Au(JohnPhos)(NTf2)] (7.7 mg, 0.01 mmol) in DCE (0.6 mL) was prepared. Then a solution of 
indole 1p (58.1 mg, 0.4 mmol) in DCE (0.7 mL) was added and the mixture stirred for 1 min 
under nitrogen. The vial was then sealed and heated at 150 °C for 1h in a single-mode microwave 
synthesizer. The solvent was removed at reduced pressure and the resulting crude was purified by 
flash column chromatography, affording indoline (±)4d (38 mg, 55%) as a white wax. 1H-NMR 
(200 MHz, CDCl3): δ 7.78 (d, J = 8.2 Hz, 2H), 7.34 (d, J = 7.9 Hz, 2H), 7.10 (t, J = 7.6 Hz, 1H), 
6.92 (d, J = 7.2 Hz, 1H), 6.65 (t, J = 7.3 Hz, 1H), 6.40 (d, J = 7.8 Hz, 1H), 5.12 (s, 1H), 3.61-3.47 
(m, 1H), 3.13-2.95 (m, 4H), 2.45 (s, 3H), 1.93 (ddd, J = 12.4, 5.8, 2.7 Hz, 1H), 1.39 (m, 1H), 1.14 
(s, 3H). 13C-NMR (50 MHz, CDCl3): δ 150.2 (C), 143.8 (C), 137.1 (C), 133.4 (C), 130.0 (2 x 
CH), 128.7 (CH), 127.5 (2 x CH), 122.1 (CH), 117.9 (CH), 106.2 (CH), 91.3 (CH), 53.3 (C), 48.7 
(CH2), 39.7 (CH2), 31.6 (CH3), 24.6 (CH3), 21.7 (CH3). ESI-MS m/z 365 [M + Na
+, 38]. Calcd. 
for C19H22N2O2S [342.46]: C 66.64, H 6.48, N 8.18; found: C 66.86, H 6.33, N 8.01. 
(±)-(3a,8a-cis)-3a-allyl-8-methyl-1-tosyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indole ((±)4e). 
Entry 8, scheme 6. In a nitrogen flushed vial a solution of aziridine 2b (39.5 mg, 0.2 mmol) and 
[Au(JohnPhos)(NTf2)] (7.7 mg, 0.01 mmol) in DCE (0.6 mL) was prepared. Then a solution of 
indole 1s (68.5 mg, 0.4 mmol) in DCE (0.7 mL) was added and the mixture stirred for 1 min under 
nitrogen. The vial was then sealed and heated at 150 °C for 1h in a single-mode microwave 
synthesizer. The solvent was removed at reduced pressure and the resulting crude was purified by 
flash column chromatography, affording indoline (±)4e (33 mg, 45%) as a white wax. 1H-NMR 
(300 MHz, CD2Cl2): δ 7.77 (d, J = 8.3 Hz, 2H), 7.39 (d, J = 7.9 Hz, 2H), 7.10 (td, J = 7.7, 1.3 Hz, 
1H), 6.94 (dd, J = 7.3.1.3 Hz, 1H), 6.65 (td, J = 7.3, 1.0 Hz, 1H), 6.40 (dd, J = 7.9, 0.7 Hz, 1H), 
5.42 (m, 1H), 5.16 (s, 1H), 4.97 (m, 1H), 4.92 (m, 1H), 3.60 (m, 1H), 2.96 (m, 4H), 2.47 (s, 3H), 
2.30 (m, 1H), 2.06 (m, 1H), 1.87 (m, 1H), 1.42 (m, 1H). 13C-NMR (75 MHz, CD2Cl2): δ 151.1 
(C), 144.1 (C), 137.1 (C), 134.1 (CH), 131.6 (C), 130.1 (2 x CH), 128.7 (CH), 127.4 (2 x CH), 
122.8 (CH), 118.1 (C), 117.5 (CH), 105.8 (CH), 88.4 (CH), 57.3 (C), 48.4 (CH2), 42.7 (CH2), 37.8 
(CH2), 31.3 (CH3), 21.5 (CH3). ESI-MS m/z 391 [M + Na
+, 100]. Calcd. for C21H24N2O2S 
[368.49]: C 68.45, H 6.56, N 7.60; found: C 68.40, H 6.59, N 7.55. 
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